No Data
No Data
There Are Reasons To Feel Uneasy About Anhui Huaheng Biotechnology's (SHSE:688639) Returns On Capital
Huaan Securities: Chemical industry cycle under pressure repair expected Supply side rebound helps boost economic recovery.
As the economy gradually recovers, continuous optimization of the supply side, the chemical industry is the strongest spear in the pro-cyclical direction, with global competitive advantages, and the industry is expected to enter an upswing cycle of prosperity.
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers
Anhui Huaheng Biotechnology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Anhui Huaheng Biotechnology Co., Ltd.
Weak expansion of sales channels? Leading synthetic biology company Huaheng Biological's net profit fell more than 20% in the first half of the year.
Due to increased competition and rising costs, Huaheng Biotech's net income for the first half of the year fell by 21.72%. It is stated that the sales channels for the core product L-Xeonine need to be further expanded, and market share needs to be increased. The registered and effective issuance plan of Huaheng Biotech has been registered and effective, but it is stated that if the project cannot generate benefits as expected or the actual income is lower than expected, there may be a risk of reduced profitability.
No Data
No Data